Answers are grounded in this paper and cite their sources.
Systematic review explores AI’s role in tailoring semaglutide therapy for type 2 diabetes, indicating future research directions.
Significant gaps remain a persistent challenge, including the need for large-scale randomized controlled trials, longer follow-up periods, explainable AI models, regulatory validation, and practical strategies for routine clinical implementation. The findings emphasize the AI's potential to transform semaglutide therapy while delineating important paths for future research.
No takes yet. Share an insight, caveat, or question.
Barakat et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: